Morepen Laboratories Limited (MOREPENLAB.BO)
INR 49.26
(3.05%)
INR 49.26
(3.05%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -231.17 Million INR | -760.82% |
| 2022 | 34.98 Million INR | 26.46% |
| 2021 | 27.66 Million INR | 111.37% |
| 2020 | -243.41 Million INR | -14134.62% |
| 2019 | -1.71 Million INR | -107.28% |
| 2018 | 23.48 Million INR | -73.45% |
| 2017 | 88.48 Million INR | -78.93% |
| 2016 | 419.88 Million INR | -41.32% |
| 2015 | 715.53 Million INR | 28.57% |
| 2014 | 556.52 Million INR | -16.76% |
| 2013 | 668.6 Million INR | -24.98% |
| 2012 | 891.2 Million INR | -18.52% |
| 2011 | 1.09 Billion INR | -13.27% |
| 2010 | 1.26 Billion INR | -9.04% |
| 2009 | 1.38 Billion INR | -49.75% |
| 2008 | 2.75 Billion INR | -0.43% |
| 2007 | 2.77 Billion INR | -35.59% |
| 2006 | 4.3 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 100.0% |
| 2023 Q4 | -231.17 Million INR | -139.97% |
| 2023 Q1 | 563.05 Million INR | 1509.51% |
| 2023 Q2 | 44.69 Million INR | -92.06% |
| 2023 Q3 | 578.43 Million INR | 1194.3% |
| 2023 FY | -231.17 Million INR | -760.82% |
| 2022 FY | 34.98 Million INR | 26.46% |
| 2022 Q3 | 406.48 Million INR | 246.6% |
| 2022 Q4 | 34.98 Million INR | -91.39% |
| 2022 Q1 | 459.7 Million INR | 1561.75% |
| 2022 Q2 | 117.27 Million INR | -74.49% |
| 2021 Q1 | 678.94 Million INR | 378.93% |
| 2021 FY | 27.66 Million INR | 111.37% |
| 2021 Q2 | -86.58 Million INR | -112.75% |
| 2021 Q4 | 27.66 Million INR | -94.63% |
| 2021 Q3 | 515.51 Million INR | 695.36% |
| 2020 FY | -243.41 Million INR | -14134.62% |
| 2020 Q2 | -148.11 Million INR | -138.09% |
| 2020 Q4 | -243.41 Million INR | -135.76% |
| 2020 Q3 | 680.71 Million INR | 559.59% |
| 2020 Q1 | 388.8 Million INR | 22837.08% |
| 2019 Q2 | 126.44 Million INR | -61.09% |
| 2019 Q4 | -1.71 Million INR | -100.6% |
| 2019 FY | -1.71 Million INR | -107.28% |
| 2019 Q1 | 324.97 Million INR | 1283.59% |
| 2019 Q3 | 282.85 Million INR | 123.7% |
| 2018 Q4 | 23.48 Million INR | -84.86% |
| 2018 FY | 23.48 Million INR | -73.45% |
| 2018 Q3 | 155.14 Million INR | 218.95% |
| 2018 Q2 | -130.42 Million INR | -319.8% |
| 2018 Q1 | 59.33 Million INR | -32.94% |
| 2017 Q1 | 70.04 Million INR | 0.0% |
| 2017 FY | 88.48 Million INR | -78.93% |
| 2017 Q4 | 88.48 Million INR | 0.0% |
| 2016 FY | 419.88 Million INR | -41.32% |
| 2015 FY | 715.53 Million INR | 28.57% |
| 2014 FY | 556.52 Million INR | -16.76% |
| 2013 FY | 668.6 Million INR | -24.98% |
| 2012 FY | 891.2 Million INR | -18.52% |
| 2011 FY | 1.09 Billion INR | -13.27% |
| 2010 FY | 1.26 Billion INR | -9.04% |
| 2009 FY | 1.38 Billion INR | -49.75% |
| 2008 FY | 2.75 Billion INR | -0.43% |
| 2007 FY | 2.77 Billion INR | -35.59% |
| 2006 FY | 4.3 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 105.98% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 106.259% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 91.868% |
| Granules India Limited | 9.28 Billion INR | 102.489% |
| Indoco Remedies Limited | 6.47 Billion INR | 103.57% |
| Achyut Healthcare Limited | -3.74 Million INR | -6071.223% |
| Ajanta Pharma Limited | -954.9 Million INR | 75.791% |
| Alkem Laboratories Limited | -1.6 Billion INR | 85.636% |
| Alpa Laboratories Limited | 35.36 Million INR | 753.717% |
| Brooks Laboratories Limited | 49.48 Million INR | 567.16% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 95.388% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 107.007% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 80.033% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 101.79% |
| Eris Lifesciences Limited | 13.8 Billion INR | 101.674% |
| FDC Limited | -57.75 Million INR | -300.287% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 94.605% |
| Gufic Biosciences Limited | 3.19 Billion INR | 107.237% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 94.434% |
| Ipca Laboratories Limited | 11.41 Billion INR | 102.025% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 83.368% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 111.96% |
| Lasa Supergenerics Limited | 205.79 Million INR | 212.33% |
| Laurus Labs Limited | 24.38 Billion INR | 100.948% |
| Lupin Limited | 17.19 Billion INR | 101.345% |
| Mankind Pharma Limited | -9.9 Billion INR | 97.667% |
| Medicamen Biotech Limited | 160.31 Million INR | 244.199% |
| Medico Remedies Limited | 78.67 Million INR | 393.827% |
| Megasoft Limited | 1.28 Billion INR | 117.982% |
| NATCO Pharma Limited | -5.81 Billion INR | 96.026% |
| Piramal Pharma Limited | 42.27 Billion INR | 100.547% |
| RPG Life Sciences Limited | -364.7 Million INR | 36.613% |
| Sigachi Industries Limited | 859.94 Million INR | 126.882% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 99.681% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 259.457% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 600.258% |
| Unichem Laboratories Limited | 931.91 Million INR | 124.806% |
| Wanbury Limited | 1.1 Billion INR | 120.904% |
| Windlas Biotech Limited | -273.04 Million INR | 15.333% |
| ZIM Laboratories Limited | 983.6 Million INR | 123.503% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 105.909% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 75.454% |
| Divi's Laboratories Limited | -39.77 Billion INR | 99.419% |
| Hester Biosciences Limited | 2.29 Billion INR | 110.092% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 90.154% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 7.081% |
| Bal Pharma Limited | 1.26 Billion INR | 118.295% |
| Strides Pharma Science Limited | 23.25 Billion INR | 100.994% |
| Venus Remedies Limited | -267.7 Million INR | 13.644% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 108.851% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 103.754% |
| Shilpa Medicare Limited | 9.06 Billion INR | 102.549% |
| Aarti Drugs Limited | 5.54 Billion INR | 104.166% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 79.009% |
| Suven Life Sciences Limited | -1.63 Billion INR | 85.841% |
| Ind-Swift Limited | 9.5 Billion INR | 102.431% |
| Valiant Laboratories Limited | -295.03 Million INR | 21.644% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 108.194% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 102.305% |
| Themis Medicare Limited | 764.96 Million INR | 130.22% |
| Hikal Limited | 7.96 Billion INR | 102.902% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 100.726% |
| Sequent Scientific Limited | 4.17 Billion INR | 105.532% |
| Novartis India Limited | -5.89 Billion INR | 96.076% |
| Wockhardt Limited | 18.27 Billion INR | 101.265% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 100.854% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -1153.247% |
| Neuland Laboratories Limited | -214.05 Million INR | -7.996% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 292.582% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 123.69% |